AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Celcuity Inc. Soars 245.53% on Positive Clinical Trial Results
Generated by AI AgentAinvest Pre-Market Radar
Monday, Jul 28, 2025 8:15 am ET1min read
Aime SummaryOn July 28, 2025,
experienced a remarkable surge of 245.53% in pre-market trading, driven by significant developments in its clinical trials.Celcuity Inc. announced topline results from its Phase 3 VIKTORIA-1 trial, revealing a 76% lower risk of disease progression and a 7.3-month gain in progression-free survival (PFS) for the PIK3CA wild-type cohort. These findings are clinically meaningful and have sparked optimism among investors.
The company plans to submit a New Drug Application (NDA) in the fourth quarter of 2025, with full data to follow. This milestone is expected to further bolster investor confidence and potentially drive additional gains in the stock price.
Celcuity's breakthrough results have positioned the company as a leader in the development of innovative breast cancer treatments, attracting significant market attention and investment interest.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Getty Images (NYSE:GETY) surges 5.51% on renewed investor confidence
Jan.02 2026
Olaplex Holdings (NASDAQ: OLPX) shares plunged 7.59% on mixed analyst outlooks and shifting institutional positioning.
Jan.02 2026
The Real Brokerage shares surge 7.04% on Jan. 2 2026 driven by regulatory tailwinds and restructuring optimism
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership and FDA Breakthrough Therapy Designation.
Jan.02 2026
Vanda Pharmaceuticals shares surge 25.46% on partnership and FDA breakthrough designation
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet